尿激酶与组织型纤溶酶原激活剂静脉溶栓治疗急性心肌梗塞的对比研究

为比较尿激酶（UK）及组织型纤溶酶原激活剂（t-PA）静脉溶栓辅以阿司匹林及肝素对急性心肌梗塞的效果及其副作用。对急性心肌梗塞患者发病6h内者，42例给予静脉UK15例静脉内t-PA溶栓辅以静脉肝素及阿司匹林治疗。结果表明，t-PA组、UK组临床血管再通率分别为86．7％与57．1％（P＜0．05），前者消化道与呼吸道出血并发症为13．3％，而后者为0（P＜0．05）。本研究提示静脉t-PA溶栓血管再通率显著高于静脉UK，但出血合并症的发生t-PA组显著高于UK组。

The comparison of intravenous thrombolytic therapy with Urokinase and tissue plasminogen activator plus intravenous heparin and Aspirin in patients with acute myocardial infarction

To compare the effectiveness and complications of intravenous Urokinase (UK) and tissue plasminogen activator (t-PA) plus intravenous heparin and Aspirin in patients with acute myocardial infarction (AMI). 15 patients in t-PA group and 42 patients in UK group were included in the study, and either of them were simultaneously treated with intravenous UK t-PA plus intravenous heparin and Aspirin. The clinical reperfusion rates in t-PA and UK group were 86. 7% and 57. 1 % (P<0.05),respectively. The major bleeding complications including respiratory and gastrointestinal bleeding in t-PA group were significantly higher than that in UK group (13. 3% vs 0,P<0. 05). One patients had hemorrhagic stroke in t-PA group and none in UK group. The patients with AMI treated with intravenous t-PA within 6 hours after onset of symptoms had significant higher reperfusion rate than those treated with intravenous UK, but hemorrhagic complications were siginificantly higher in t-PA group.